ExodusPoint Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-97,580
| Closed | -$222K | – | 2199 |
|
|
2024
Q2 | $222K | Buy |
97,580
+77,833
| +394% | +$297K | ﹤0.01% | 1380 |
|
|
2024
Q1 | $85K | Buy |
+19,747
| New | +$68.8K | ﹤0.01% | 1423 |
|
|
2023
Q1 | – | Sell |
-13,856
| Closed | -$75K | – | 2206 |
|
|
2022
Q4 | $75K | Sell |
13,856
-65,082
| -82% | -$545K | ﹤0.01% | 1531 |
|
|
2022
Q3 | $986K | Buy |
78,938
+67,870
| +613% | +$775K | 0.01% | 1113 |
|
|
2022
Q2 | $55K | Sell |
11,068
-15,139
| -58% | -$83.8K | ﹤0.01% | 1795 |
|
|
2022
Q1 | $199K | Buy |
26,207
+4,200
| +19% | +$39.8K | ﹤0.01% | 1916 |
|
|
2021
Q4 | $225K | Sell |
22,007
-13,167
| -37% | -$168K | ﹤0.01% | 1784 |
|
|
2021
Q3 | $472K | Buy |
+35,174
| New | +$573K | 0.01% | 1431 |
|
|
2021
Q1 | – | Sell |
-29,565
| Closed | -$532K | – | 2703 |
|
|
2020
Q4 | $532K | Sell |
29,565
-16,397
| -36% | -$245K | 0.01% | 1211 |
|
|
2020
Q3 | $531K | Buy |
45,962
+12,075
| +36% | +$199K | 0.01% | 982 |
|
|
2020
Q2 | $822K | Buy |
+33,887
| New | +$560K | 0.02% | 842 |
|
|
2019
Q4 | – | Sell |
-9,147
| Closed | -$208K | – | 1970 |
|
|
2019
Q3 | $208K | Buy |
+9,147
| New | +$288K | 0.01% | 1110 |
|
ExodusPoint Capital Management's GTHX Position: Q3 2024 in Review
ExodusPoint Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 97,580 shares — an estimated $222K sold.
ExodusPoint Capital Management first reported a position in GTHX in Q3 2019 and held it in 12 quarters. The position peaked at $986K in Q3 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- ExodusPoint Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- ExodusPoint Capital Management sold 97,580 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $222K.
- ExodusPoint Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2019 and held it in 12 quarters.
- ExodusPoint Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $986K in Q3 2022.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.